Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: a prospective multicenter phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) comparing TCG with standard TC

A. DU BOIS; J. SEHOULI; B. LUND; F. JOLY; J. HUOBER; T. S. JENSEN; E. LEVY; V. HEILMANN; K. BOMAN; A. C. HARDY-BESSARD; A. BURGES; J. MÄENPÄÄ; E. PUJADE-LAURAINE; J. PFISTERER; M. GROPP; A. STAEHLE; P. WIMBERGER; C. JACKISCH; B. SCHMALFELDT; A. BELAU; S. LOIBL; K. WOLLSCHLAEGER; U. CANZLER; J. ROCHON

doi:10.1136/ijgc-00009577-200511001-00007

Citation Tools

Articles

Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: a prospective multicenter phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) comparing TCG with standard TC

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: DU BOIS A, SEHOULI J, LUND B for the GCIG Intergroup of AGO-OVAR, NSGO, and GINECO, et al

Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: a prospective multicenter phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) comparing TCG with standard TC

International Journal of Gynecologic Cancer 2005;15:224-225.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password